BioSpace News Archive

$2 million grant will fund immune biomarker analysis in Phase 1 clinical study of SQ3370 as well as manufacturing process development SQ3370 is a click-activated protodrug therapy currently in a Phase 1 clinical study in advanced sarcomas and other solid tumors

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked #4 in overall corporate reputation among nearly 50 pharmaceutical and biotech companies based on PatientView’s annual survey of 1,920 patient groups worldwide.

Allegro Ophthalmics , LLC, a privately held biopharmaceutical company focused on the development of novel integrin regulating therapies for the treatment of ocular diseases, today announced that four scientific posters involving risuteganib, the company’s lead investigational compound in retina, will be presented during the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

As the name suggests, prostate cancer occurs in the prostate area of men, which basically is a small gland shaped like a walnut, which produces seminal fluid that helps maintain sperms and facilitates their transportation.

Prescription drugs comprise various types of vaccines and therapies for the treatment and management of chronic and acute diseases. These disorders include types of cancer, cardiovascular diseases, diabetes, and also orphan diseases.

Pemetrexed, marketed under the brand, Alimta, by Eli Lilly and Company is used as a medication for the treatment of non-small cell lung cancer and mesothelioma.

Monoclonal antibody C6-17 designed to target mutant huntingtin protein (mtHTT) and to reduce spread of Huntington’s disease pathology

Extensive research and development in the medical field has aided the market to grow fast. Adhesion barriers are medical devices that are used to descend or reduce post-operative complications.

Dr. Douglas Arnold from The Neuro at McGill University receives AI & MS Discovery Grant supported by TD Bank Group through the TD Ready Commitment.

Enzyvant announced the resubmission of the Biologics Licensing Application to the U.S. Food and Drug Administration for RVT-802, cultured human thymus tissue.